May28, 2010

To Whom It May Concern

KYORIN Co., Ltd.
5, Kanda Surugadai 2-chome,
Chiyoda-ku, Tokyo
Securities Code: 4569; TSE 1st Section

RELEASE OF "MUCODYNE® DS50%"

KYORIN Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Keiji Hirai), a subsidiary of KYORIN Co., Ltd. announces the release of Mucodyne® DS50% (Nonproprietary name: L-Carbocisteine), a mucoregulating drug (for adults and children) today.

Since the release of Mucodyne® Tablets (for adults) in January 1981, Kyorin Pharmaceutical Co., Ltd. has made planned and consistent efforts to meet the needs of patients and medical workers, by developing new formulations and obtaining new indications. (Please refer to the Summary of Product Profile in the attachment for the present formulation and indications.)

The Company hopes that the new Mucodyne® DS50% will improve convenience for adult and pediatric patients, and contribute to treatment in such fields as pulmonology and otology.

For Further information, Contact:
KYORIN Co., Ltd.
Management Planning Department
Telephone: +81-3-3293-3414
Fax: +81-3-3293-3454

＜Product Profile for MUCODYNE® DS 50%＞

PRODUCT NAME	MUCODYNE® DS50%
NONPROPRIETARY NAME	L-Carbocisteine（JAN）
INDICATIONS	**For adults** Expectoration for the following diseases: Upper respiratory inflammation (pharyngitis, laryngitis), acute bronchitis, bronchial asthma, chronic bronchitis, bronchiectasis and pulmonary tuberculosis. Drainage in chronic sinusitis. **For children** Expectoration for the following diseases: Upper respiratory inflammation (pharyngitis, laryngitis), acute bronchitis, bronchial asthma, chronic bronchitis, bronchiectasis and pulmonary tuberculosis. Drainage in chronic sinusitis. Drainage in otitis media with effusion.
DOSAGE AND ADMINISTRATION	**For adults** For oral use, the usual dose for adults is 500 mg of L-carbocisteine (1.0g of MUCODYNE® DS50%) three times daily. MUCODYNE® DS50% should be suspended immediately before use. The dose may be adjusted according to age and symptoms. **For children** For oral use, the usual dose for children is 10 mg/kg of L-carbocisteine (0.02g/kg of MUCODYNE® DS50%) three times daily. MUCODYNE® DS50% should be suspended immediately before use. The dose may be adjusted according to age and symptoms.
NHI PRICE	¥37.70/g
PACKAGING	Boxes of 120 packets (1.0g×120 packets) Bottles of 100 g, and bottles of 500 g.

Underlined sections correspond to changes from MUCODYNE® DS 33.3%.

Reference: Indications and marketing launch for each MUCODYNE formulation

Formulations	For adults	For children	Marketing launch
MUCODYNE® Tablets 250mg	○	－	Date of initial marketing in Japan: July 2001 ＊ Marketed in January 1981 under the name of MUCODYNE® Tablets
MUCODYNE® Tablets 500mg	○	－	Date of initial marketing in Japan: October 1996
MUCODYNE® Fine Granules 50%	○	－	Date of initial marketing in Japan: November 1987
MUCODYNE® Syrup 5%	－	○	Date of initial marketing in Japan: October 1987
MUCODYNE® DS 33.3%	○	○	Date of initial marketing in Japan: October 2001
MUCODYNE® DS 50%	○	○	Date of initial marketing in Japan: May 2010